The estimated Net Worth of Yuchun Lee is at least $3.18 Millón dollars as of 27 January 2023. Mr. Lee owns over 1,429 units of Vertex Pharmaceuticals stock worth over $1,568,541 and over the last 12 years he sold VRTX stock worth over $1,088,166. In addition, he makes $526,441 as Independent Director at Vertex Pharmaceuticals.
Sign up
Mr. Lee VRTX stock SEC Form 4 insiders trading
Yuchun has made over 25 trades of the Vertex Pharmaceuticals stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 1,429 units of VRTX stock worth $103,088 on 27 January 2023.
The largest trade he's ever made was exercising 8,000 units of Vertex Pharmaceuticals stock on 25 January 2023 worth over $577,120. On average, Yuchun trades about 2,092 units every 75 days since 2012. As of 27 January 2023 he still owns at least 3,304 units of Vertex Pharmaceuticals stock.
You can see the complete history of Mr. Lee stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Yuchun Lee biography
Yuchun Lee is Independent Director of Vertex Pharmaceuticals Incorporated. Mr. Lee serves as an Executive in Residence and Partner of General Catalyst Partners, a venture capital firm, positions he has held since April of 2013. Mr. Lee also serves as the Chief Executive Officer of Allego, Inc. and is Executive Chairman of Clarabridge, Inc. Mr. Lee was the Vice President of IBM’s Enterprise Marketing Management Group from November 2010 through January 2013. Mr. Lee co-founded Unica Corporation, a provider of software and services used to automate marketing processes, in 1992, and was Unica’s President and/or Chief Executive Officer from 1992 through November 2010, when Unica was acquired by IBM. From 1989 to 1992, Mr. Lee was a senior consultant at Digital Equipment Corporation, a supplier of general computing technology and consulting services. Mr. Lee holds a B.S. and an M.S. in electrical engineering and computer science from the Massachusetts Institute of Technology and an M.B.A. from Babson College.
What is the salary of Yuchun Lee?
As the Independent Director of Vertex Pharmaceuticals, the total compensation of Yuchun Lee at Vertex Pharmaceuticals is $526,441. There are 17 executives at Vertex Pharmaceuticals getting paid more, with Jeffrey Leiden having the highest compensation of $18,790,000.
How old is Yuchun Lee?
Yuchun Lee is 53, he's been the Independent Director of Vertex Pharmaceuticals since 2012. There are 14 older and 9 younger executives at Vertex Pharmaceuticals. The oldest executive at Vertex Pharmaceuticals, Inc. is William Young, 75, who is the Independent Director.
What's Yuchun Lee's mailing address?
Yuchun's mailing address filed with the SEC is C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON, MA, 02210.
Insiders trading at Vertex Pharmaceuticals
Over the last 21 years, insiders at Vertex Pharmaceuticals have traded over $934,925,905 worth of Vertex Pharmaceuticals stock and bought 308,652 units worth $12,298,449 . The most active insiders traders include Lloyd Carney, Jeffrey M Leiden y Joshua S Boger. On average, Vertex Pharmaceuticals executives and independent directors trade stock every 5 days with the average trade being worth of $4,747,875. The most recent stock trade was executed by Jeffrey M Leiden on 30 August 2024, trading 3,784 units of VRTX stock currently worth $1,888,216.
What does Vertex Pharmaceuticals do?
Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
What does Vertex Pharmaceuticals's logo look like?
Complete history of Mr. Lee stock trades at Vertex Pharmaceuticals
Vertex Pharmaceuticals executives and stock owners
Vertex Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Jeffrey Leiden,
Executive Chairman of the Board -
Stuart Arbuckle,
Executive Vice President, Chief Commercial Officer -
Reshma Kewalramani,
President, Chief Executive Officer, Director -
Amit Sachdev,
Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO -
David Altshuler,
Executive Vice President - Global Research, Chief Scientific Officer -
Michael Parini,
Executive Vice President, Chief Legal and Administrative Officer -
Dr. Reshma Kewalramani FASN, M.D.,
CEO, Pres & Director -
Charles Wagner,
Chief Financial Officer, Executive Vice President -
Paul Silva,
Senior Vice President, Controller -
Dr. Jeffrey Marc Leiden M.D., Ph.D.,
Exec. Chairman -
Stuart A. Arbuckle B.Sc.,
Exec. VP & COO -
Dr. David M. Altshuler,
Exec. VP of Global Research & Chief Scientific Officer -
Charles F. Wagner Jr.,
Exec. VP & CFO -
Bruce Sachs,
Co-Lead Independent Director -
Margaret McGlynn,
Independent Director -
Terrence Kearney,
Independent Director -
Sangeeta Bhatia,
Independent Director -
Yuchun Lee,
Independent Director -
William Young,
Independent Director -
Alan Garber,
Independent Director -
lloyd Carney,
Independent Director -
Michael Partridge,
Vice President - Investor Relations -
Diana McKenzie,
Independent Director -
Nia Tatsis,
Senior Vice President, Chief Regulatory Officer -
John Gray,
Senior Vice President, Genetic Therapies -
Gerald Bruce,
Executive Vice President, Commercial Operations -
Carmen Bozic,
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer -
Joy Liu,
Sr. VP & Gen. Counsel -
Damian W. Wilmot Esq.,
Sr. VP, Chief Risk and Compliance Officer -
Mike Tirozzi,
SVP and Chief Information & Data Officer -
Kristen Ambrose,
Chief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. Services -
Joshua S Boger,
Chairman & CEO -
Elaine Ullian,
Director -
Ian F Smith,
SVP & CFO -
Jeffrey Chodakewitz,
SVP GMDA, CMO -
Thomas Graney,
Chief Financial Officer -
Michel Lagarde,
Director -
Wayne Joseph Riley,
Director -
Peter Mueller,
CSO & SVP Drug Discovery -
Thomas Connolly,
SVP, Human Resources -
Kenneth L Horton,
EVP & Chief Legal Officer -
Megan E Pace,
SVP, Corp. Communications -
Christiana Stamoulis,
SVP, Corp Strategy & Bus Devlp -
Matthew Emmens,
Director -
Lisa Kelly,
SVP, Human Resources -
Dennis L Winger,
Director -
Eugene Cordes,
Director -
Nancy Wysenski,
EVP & Chief Commercial Officer -
David T Howton,
SVP -
Kenneth S Boger,
SVP & General Counsel -
Kurt Graves,
EVP, Chief Commercial Officer -
John J Alam,
SVP, Drug Eval. & Appr. -
Stuart J Collinson,
Director -
Charles A Sanders,
Director -
Roger W Brimblecombe,
Director -
Freda C Lewis Hall,
EVP, Medicines Development -
Eve Elizabeth Slater,
Director -
Richard C Garrison,
SVP, Organizational Developmen -
Johanna Messina Power,
Controller -
Victor A Hartmann,
EVP, Strategic & Corp. Devlp. -
Eric Brandt,
Director -
Lynne H Brum,
VP, Corp. Comm.&Financial Plan -
Paul A Negulescu,
VP, Research -
John F Niblack,
Director -
Iain P M Buchanan,
VP, European Operations -
Vicki L Sato,
President -
N Anthony Coles,
SVP, Comm. Ops. -
Bastiano Sanna,
EVP, Cell & Genetic Therapies -
Joy Liu,
SVP, General Counsel -
Kristen Ambrose,
SVP & Chief Accounting Officer -
Suketu Upadhyay,
Director -
Jonathan Biller,
EVP and Chief Legal Officer -
Nancy Thornberry,
Director -
Edward Morrow Iii Atkinson,
EVP, Chief Technical Ops. Off. -
Jennifer Schneider,
Director